Vytorin - the mechanism for no-clinical-benefit ?

This pre-print manuscript (in press, Atherosclerosis) doesn't seem to have been mentioned on a single blog - so I thought I would stick it up here. Could it explain all sorts of anti-pleotropic effects, and possible paradoxical worsening of atherosclerosis (or lack of effect) of Vytorin in the ENHANCE study?

Any lipidologists out there please interpret.

Ioanna Gouni-Berthold et. al. Atherosclerosis (2008) in Press: Effects of ezetimibe and/or simvastatin on LDL receptor protein expression and on LDL receptor and HMG-CoA reductase gene expression: A randomized trial in healthy men.



Earlier|Later|Main Page

Labels:

Comments on: Vytorin - the mechanism for no-clinical-benefit ?

 

post a comment

Links to: Vytorin - the mechanism for no-clinical-benefit ?

Create a Link